The clinicopathological relevance of pretransplant anti-angiotensin II type 1 receptor antibodies in renal transplantation

Lee, Juhan; Huh, Kyu Ha; Park, Yongjung; Park, Borae G.; Yang, Jaeseok; Jeong, Jong Cheol; Lee, Joongyup; Park, Jae Berm; Cho, Jang‐Hee; Lee, Sik; Ro, Han; Han, Seungyeup; Kim, Myoung Soo; Kim, Yu Seun; Kim, Sung Joo; Kim, Chan‐Duck; Chung, Wookyung; Park, Sung-Bae; Ahn, Curie

doi:10.1093/ndt/gfv375

Cited by 36 publications

(51 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pretransplant sensitization against AT1R, in patients without DSA, has been associated a higher prevalence of intimal arteritis and was demonstrated to be an independent predictor of vascular or ABMR rejection . Overall, our results confirm that the pretransplant presence of AT1R‐abs with or without concomitant DSA is an independent predictor of acute rejection, as previously reported …”

Section: Discussionsupporting

confidence: 89%

“…Studied cohort median value was 8.2 UI/mL (interquartile range: 6.4–10.0). A value of 10 UI/mL was considered to be the cut‐off for positivity, given that it was the 3rd quartile value in our cohort and considering its association with clinical outcomes as previously published …”

Section: Methodsmentioning

confidence: 99%

“…AT1R‐abs appear to have direct effects, via induction of the Erk 1/2 signal transduction cascade, on endothelial cells . Pretransplant sensitization against angiotensin II type 1 receptor has been correlated in KT with acute rejection, de novo DSA emergence and higher risk of graft loss Nevertheless, these findings have not been reproduced by other reports …”

mentioning

confidence: 88%

See 2 more Smart Citations

Deleterious effect of anti‐angiotensin II type 1 receptor antibodies detected pretransplant on kidney graft outcomes is both proper and synergistic with donor‐specific anti‐HLA antibodies

Malheiro

Tafulo²,

Dias

et al. 2019

Nephrology

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Deleterious effect of anti‐angiotensin II type 1 receptor antibodies detected pretransplant on kidney graft outcomes is both proper and synergistic with donor‐specific anti‐HLA antibodies

Malheiro

Tafulo²,

Dias

et al. 2019

Nephrology

View full text Add to dashboard Cite

show abstract

“…After excluding duplicates, the titles and abstracts from the remaining 99 records were screened. Of these, 21 articles were selected for full text review, and nine articles were ultimately retained in our meta-analysis (see Figure 1) [12,13,14,15,16,21,22,23,24]. …”

Section: Resultsmentioning

confidence: 99%

“…Moreover, AR after kidney allograft transplantation frequently progresses to persistent chronic rejection and dysfunction of kidney allograft, and ultimately results in kidney graft failure [11], indicating that AT1R-Abs may also influence the long-term outcomes of kidney allograft transplantation. Currently, several studies have shown that AT1R-Abs might be associated with an increased risk of acute rejection and kidney graft failure [12,13,14]; however, the results are inconsistent and inconclusive [15,16]. …”

Section: Introductionmentioning

confidence: 99%

The Presence of Anti-Angiotensin II Type-1 Receptor Antibodies Adversely Affect Kidney Graft Outcomes

Zhang

Wang

Liang

et al. 2017

IJERPH

View full text Add to dashboard Cite

The aim of this study was to determine whether anti-angiotensin type 1 receptor antibodies (AT1R-Abs) are related to acute rejection (AR) and kidney graft failure in renal transplantation. We searched electronic databases including MEDLINE, EMBASE, and the ISI Web of Science databases for all studies on the association between anti-angiotensin type 1 receptor antibodies and kidney allograft outcomes updated to November 2016. Reference lists from included articles were also reviewed. The pooled relative risks (RRs) with 95% confidence intervals (CIs) were extracted or calculated using a random-effects model. The potential sources of heterogeneity and publication bias were estimated. Nine studies enrolling 1771 subjects were retrieved in the meta-analysis. AT1R-Abs showed significant associations with increased risk of AR (RR = 1.66; 95% CI, 1.23–2.09). In addition, a significant relationship was found between AT1R-Abs and kidney graft failure compared with AR (RR = 3.02; 95% CI, 1.77–4.26). The results were essentially consistent among subgroups stratified by participant characteristics. These results demonstrated that the AT1R-Abs were associated with an elevated risk of kidney allograft outcomes, especially with kidney graft failure. Large-scale studies are still required to further verify these findings.

show abstract

Association between anti‐endothelial antigen antibodies and allograft rejection in kidney transplantation

Lee,

Shin,

Kim

et al. 2023

Clinical Laboratory Analysis

View full text Add to dashboard Cite

BackgroundEndothelial cells are vital in the transplant immune system as semiprofessional antigen‐presenting cells. Few studies have investigated the importance of anti‐endothelin subtype A receptor (ETAR) antibodies in kidney transplantation. Here, we aimed to analyze the association between anti‐angiotensin II type I receptor (AT1R) and anti‐ETAR antibodies and the association between the presence of anti‐endothelial antibodies and the risk of allograft rejection in kidney transplantation.MethodsIn total, 252 patients who underwent kidney transplantation were enrolled in this study. Antibodies for human leukocyte antigens (HLAs) and non‐HLAs were analyzed immediately before transplantation. Patients were categorized based on the occurrence of antibody‐mediated rejection (AMR) or T‐cell‐mediated rejection (TCMR) by 2017 Banff classification. All p‐values were two‐tailed, and statistical significance was set at p < 0.05.ResultsPatients with anti‐AT1R antibodies had a 3.49‐fold higher risk of TCMR than those without anti‐AT1R antibodies. Patients with anti‐ETAR antibodies had a 5.84‐fold higher risk of AMR than those without anti‐ETAR antibodies. The hazard ratio of AMR in patients with both HLA DSAs and anti‐ETAR antibodies, relative to patients without anti‐ETAR antibodies and HLA DSAs, was 32.85 (95% CI = 1.82–592.91).ConclusionOur findings indicated that anti‐ETAR antibodies are associated with AMR, and patients with both anti‐ETAR antibodies and de novo HLA DSAs were at a high risk of AMR.

show abstract

The clinicopathological relevance of pretransplant anti-angiotensin II type 1 receptor antibodies in renal transplantation

Abstract: Pretransplant AT1R-Abs is an independent risk factor for AR, especially acute cellular rejection, and is possibly associated with the risk of antibody-mediated injury. Pretransplant assessment of AT1R-Abs may be useful for stratifying immunologic risks.

Cited by 36 publications

References 33 publications

Deleterious effect of anti‐angiotensin II type 1 receptor antibodies detected pretransplant on kidney graft outcomes is both proper and synergistic with donor‐specific anti‐HLA antibodies

Deleterious effect of anti‐angiotensin II type 1 receptor antibodies detected pretransplant on kidney graft outcomes is both proper and synergistic with donor‐specific anti‐HLA antibodies

The Presence of Anti-Angiotensin II Type-1 Receptor Antibodies Adversely Affect Kidney Graft Outcomes

Association between anti‐endothelial antigen antibodies and allograft rejection in kidney transplantation

Contact Info

Product

Resources

About